Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109625 - COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. A combination of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and NGR-hTNF or an analog thereof for use in the treatment of primary central nervous system lymphoma in a subject, wherein the combination comprises at least one course of R-CHOP preceded by an administration of NGR- hTNF or an analog thereof.

2. The combination according to claim 1 wherein a course of R-CHOP consists of 375 mg/m2 of rituximab, 750 mg/m2 of cyclophosphamide, 50 mg/m2 of doxorubicin and 1.4 mg/m2 of vincristine.

3. The combination according to claim 1 or 2 wherein the administration of NGR- hTNF or of an analog thereof is performed before CHOP drugs.

4. The combination according to any one of previous claim wherein the NGR-hTNF administration consists of 0.8 ug/ m2.

5. The combination according to any one of previous claim comprising six courses of R-CHOP each preceded by an administration of NGR-hTNF or an analog thereof.

6. The combination according to any one of previous claim wherein the courses of R-CHOP preceded by an administration of NGR-hTNF or an analog thereof are separated by 18 to 21 days.

7. The combination according to any one of previous claim wherein primary central nervous system lymphoma relapsed or is a refractory primary central nervous system lymphoma.